# Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation

> **NCT00718146** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 130 (actual)

## Conditions studied

- Influenza
- Orthomyxoviridae Infections

## Interventions

- **BIOLOGICAL:** Split virion, inactivated Influenza vaccine
- **BIOLOGICAL:** Split virion, inactivated Influenza vaccine

## Key facts

- **NCT ID:** NCT00718146
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-09
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2014-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00718146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00718146, "Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00718146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*